What to Know Before AAD 2025: Product Snapshots of Nonsteroidal Topical Treatments for Eczema
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
WHO Recommends Flu Vaccine Composition for 2025-26 Northern Hemisphere Season as US HHS Cancels ACIP, VRBAC Meetings
Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.
Omalizumab Efficacy and Safety Shown Superior to OIT in First Head-to-Head Multi-Food Allergy Trial
Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Pediatric Anaphylaxis Study
Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.
Atopic Dermatitis Primer for AAD 2025: Dermatologist Mona Shahriari, MD, Explains the Rise in Prevalence
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
Dupilumab Reduces Specific IgE to Foods at 12 and 24 Months in Small Study
AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.
Perimenopause Symptoms May Affect More Than Half of Women as Young as Age 30
Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.
American Academy of Dermatology 2025 Prep: A Dermatologist Considers When Atopic Dermatitis Referral from Primary Care is Indicated
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
Focus on AAD 2025: Dermatologist Mona Shahriari, MD, Highlights the PCP Role in Atopic Dermatitis Care
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.
Measles Claims Life of Unvaccinated Texas Schoolchild, First US Fatality Reported Since 2015
A rural west Texas "undervaccinated" Mennonite community is the epicenter of the worst measles outbreak in the state in 30 years, the state health department reported.
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.
Sinaptica Announces Enrollment for Phase 2 Clinical Trial in Early Alzheimer Disease of Dual Neuromodulation System
The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.
Depression Increases Risk For and Accrual of Long-Term Health Disorders
Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.
Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence
Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.
Cancer Rates in Black Individuals Decline but Still Outpace Other Racial, Ethnic Groups, Says American Cancer Society
The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.
5 Final Dermatology Tips from the Midwinter Hawaii Dermatology Conference
Tips cover biologic agents and hepatitis B, 5-FU plus calcipotriene for AK, a triple treatment package for post-acne postinflammatory hyperpigmentation, and more.
Problems with Nail Pigment: 3 Cases of a Black Nail
The sudden appearance of "a black nail" can frighten a patient and should be investigated. Nail expert Boni Elewski, MD, shares 3 cases and the outcomes.
Melasma Mitigation: It All Begins with Photoprotection
Susan C Taylor, MD, is internationally recognized for her expertise in dermatologic conditions in skin of color and spoke about avoiding photodamage at the Midwinter Clinical Derm Conference.
Acne and Rosacea Insights: Experts Offer Pearls and Novel Approaches
Established therapies for these common disorders don't always lead to optimal results; experts offer new evidence-based options that may help.
Nailing Treatment of 3 Nail Disorders: Nail Lichen Planus, Psoriasis, and Onychomycosis
Systemic therapy for nail disorders, including biologics and JAK inhibitors, is gaining favor; learn more about early diagnosis and aggressive treatment from an expert.
Late Breakers in Atopic Dermatitis: Highlights and Previews with Alexandra Golant, MD
From the revolutionary approval of dupilumab to the promise of potential disease modification with OX40 inhibitors, Golant provided a wide-ranging update of the treatment space.
More 60 Dermatology Tips in 60 Minutes from the Midwinter Clinical Hawaii Derm Conference
How to treat lichenoid dermatoses, what to do when the Quant Gold is indeterminate, pocket-sized Wood lights, plus 9 more pearls from the experts.
A Case of Biologic Switching in Psoriasis and How to Optimize Outcomes with Ron Vender, MD
Switching biologic treatment for patients with moderate to severe psoriasis, needn't be daunting, Vender said; he works through a tricky case that ended very well.
FDA Approves GSK's Pentavalent Meningococcal Vaccine Penmenvy
The ACIP of the CDC will meet on February 26 to vote on recommendations for appropriate incorporation of Penmenvy into the routine vaccination schedule.
Pearls for Solving Problems when Treating Psoriasis: From the Experts
Dermatology experts share pearls to help when biologics alone are not enough, when obesity is a comorbidity with psoriasis, and when isotype switching derails therapy.
Alopecia Areata: Emerging Data and Treatment Approaches
JAK inhibitors are being used widely and successfully to treat alopecia areata, and Amy McMichaels, MD, showcased data and also discussed patient communication.
The Great Atopic Dermatitis Treatment Debate: Biologics vs JAK Inhibitors
There really is no debate - it's all about individualizing treatment for the patient, but Drs Neal Bhatia and Raj Chovatiya went head to head at Midwinter Hawaii.